美国国立综合癌症网络（NCCN）指南见解：骨髓增生异常综合征，2025年第2版

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.

作者信息

Greenberg Peter L, Stone Richard M, Abaza Yasmin, Al-Kali Aref, Anand Sarah, Ball Brian, Bennett John M, Borate Uma, Brunner Andrew M, Chai-Ho Wanxing, Curtin Peter, DeZern Amy E, Gaensler Karin, Gahvari Zhubin, Garcia-Manero Guillermo, Griffiths Elizabeth A, Haque Tamanna, Jacoby Meagan, Jonas Brian A, Keel Sioban, Khanal Rashmi, Kishtagari Ashwin, Madanat Yazan, Maness Lori J, McCurdy Shannon R, McMahon Christine, Odenike Olatoyosi, Osman Afaf, Reddy Vishnu V, Sallman David A, Sayar Hamid, Shallis Rory, Singh Abhay, Tanaka Tiffany, Thota Swapna, Kovach Emily, Nguyen Jamie, Hochstetler Cindy

机构信息

Stanford Cancer Institute.

Dana-Farber/Brigham and Women's Cancer Center.

出版信息

J Natl Compr Canc Netw. 2025 Mar;23(3):66-75. doi: 10.6004/jnccn.2025.0013.

DOI:10.6004/jnccn.2025.0013

PMID:40073835

Abstract

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.

摘要

美国国立综合癌症网络（NCCN）骨髓增生异常综合征（MDS）指南基于对近期临床证据的回顾，为MDS患者的评估、诊断及综合治疗提供建议，这些证据带来了治疗方面的重要进展，或产生了有关可能对MDS预后有重要意义的生物学因素的新信息。MDS专家多学科小组至少每年召开一次会议。在年度会议期间，该小组评估新出现的数据，以为其建议提供依据。这些NCCN指南见解回顾了近期更新内容，包括低危和高危MDS的治疗建议、治疗药物的偏好分层以及新型疗法的新出现数据。